Baseline neutrophil-to-lymphocyte ratio (NLR) and early toxicity as prognostic factors in advanced hepatocellular carcinoma patients treated with sorafenib.

e15159 Background: Sorafenib improves overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC). An elevated baseline NLR has been reported as a possible poor prognostic factor in several tumors, including HCC. Early-onset toxicity with sorafenib has also been linked with a better prognosis. Methods: Retrospective review of sorafenib-treated pts (2008-2014). Baseline NLR, overall toxicity, early toxicity rates (onset in 1st 30 days), progression-free survival (PFS) and OS were assessed. Univariate and multivariate analysis of prognostic factors for OS was performed. Results: 145 pts found. Baseline characteristics in Table 1. Overall G3-4 toxicities: fatigue (19.3%), hand-foot syndrome (HFS) (8.3%) and diarrhea (7.6%). Early toxicities (all grades): diarrhea and HFS in 42.2% and 20.8%. With a median follow-up of 43 months (mts), median PFS and OS was 4.15 (CI95% 2,5-5,8) and 6.7 mts (CI95% 4,5-8,8), respectively, with a 1-year OS of 33%. Univariate analysis: Performance status (...